Six-month visual prognosis in eyes with submacular hemorrhage secondary to age-related macular degeneration or polypoidal choroidal vasculopathy

Abstract

Thinner neurosensory retina demonstrated on OCT at baseline may be a useful prognostic sign for limited visual recovery.

Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome

“…However, the benefit was limited in eyes with submacular hemorrhage. Although submacular hemorrhage has been considered to be related with poor visual prognosis in CNV [32,33], recent evidence suggests that significant improvements in visual acuity can be achieved using anti-VEGF therapy [34][35][36]. In contrast, our patients in the hemorrhage group did not show significant visual improvement.…”

“…In our study, the mean extent of hemorrhage in eyes included in the visual outcome analysis was 11.7 disc areas. This value was greater than that reported in previous studies which investigated the treatment outcome of anti-VEGF therapy in a similar condition [34,35]. In addition, although a marked decrease in hemorrhage extent was observed during the follow-up period, at 6 months hemorrhages persisted in more than half of the eyes.…”

“…We postulate that this improvement came partly as a result of the relatively greater extent of hemorrhage in our patients. It has been reported that the large amount of hemorrhage is associated with poor visual prognosis [34,35]. In our study, the mean extent of hemorrhage in eyes included in the visual outcome analysis was 11.7 disc areas.…”

Visual prognosis of massive submacular hemorrhage in polypoidal choroidal vasculopathy with or without combination treatment

“…In addition, although photodynamic therapy (PDT) had proved to be effective in regressing polyps (reference of EVEREST), the complication rates of subretinal hemorrhage were high at 6.5%. 11,12 Dense submacular hemorrhage may mask the underlying lesion and limit the information that can be obtained from angiography. It can also impede and reduce the effect of treating the underlying lesion.…”

Subretinal tissue plasminogen activator injection to treat submacular haemorrhage during age‐related macular degeneration

“…However, our results compare favourably to those of other similar studies evaluating the natural course of submacular haemorrhage. A prospective case series by Cheung et al (2013). indicated a median improvement in VA of 0.20 LogMAR units after 6 months.…”